aln-rsv01
Nucleic acidexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00496821)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- aln-rsv01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01065935 | Phase 2 | Feb 1, 2010 | Alnylam Pharmaceuticals, Gottfried Wilhelm Leibniz Universität Hannover, University of Colorado, Denver, University of New South Wales |
| NCT00658086 | Phase 2 | Apr 1, 2008 | Alnylam Pharmaceuticals, University of Colorado, University of New South Wales |
| NCT00496821 | Phase 2 | Jul 1, 2007 | Alnylam Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 3 | 3 | 1 | 2007 |
| University of New South Wales | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Colorado | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1